ARTICLE | Company News

Ligand, Proximagen deal

September 27, 2010 7:00 AM UTC

Ligand transferred to Proximagen exclusive, worldwide rights to develop and commercialize undisclosed compounds targeting the CXC chemokine receptor 4 ( CXCR4; NPY3R). The compounds are in preclinical development to treat CNS diseases. Ligand received $250,000 up front and is eligible for undisclosed milestones and royalties. ...